[Skip to Content]
[Skip to Content Landing]
Views 636
Citations 0
Invited Commentary
June 5, 2019

Trimodal Therapy for Bladder Cancer: You Get What You Don’t Pay For

Author Affiliations
  • 1Center for Surgery and Public Health, Division of Urological Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
JAMA Surg. 2019;154(8):e191637. doi:10.1001/jamasurg.2019.1637

Trimodal therapy (TMT) is a treatment option for some patients with muscle-invasive bladder cancer. This approach combines aggressive transurethral resection, radiation therapy, and radio-sensitizing chemotherapy as an alternative to radical cystectomy with urinary diversion. In the absence of head-to-head level 1 evidence, there is now a growing body of retrospective data suggesting worse survival rates with this technique.1,2 Now added to this are data suggesting higher costs as well.3

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×